JP2010024190A - Skin barrier function ameliorator - Google Patents
Skin barrier function ameliorator Download PDFInfo
- Publication number
- JP2010024190A JP2010024190A JP2008188199A JP2008188199A JP2010024190A JP 2010024190 A JP2010024190 A JP 2010024190A JP 2008188199 A JP2008188199 A JP 2008188199A JP 2008188199 A JP2008188199 A JP 2008188199A JP 2010024190 A JP2010024190 A JP 2010024190A
- Authority
- JP
- Japan
- Prior art keywords
- cardamonin
- extract
- alpinia
- barrier function
- skin barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 12
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 claims abstract description 31
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 20
- 108060008539 Transglutaminase Proteins 0.000 claims abstract description 17
- 102000003601 transglutaminase Human genes 0.000 claims abstract description 17
- 102000007236 involucrin Human genes 0.000 claims abstract description 16
- 108010033564 involucrin Proteins 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 241000013298 Alpinia <beetle> Species 0.000 claims description 20
- 230000003780 keratinization Effects 0.000 claims description 7
- 241000269851 Sarda sarda Species 0.000 claims description 5
- 241000010428 Alpinia katsumadae Species 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 210000000434 stratum corneum Anatomy 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- -1 multilayer Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000532412 Vitex Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000009347 chasteberry Nutrition 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011403 purification operation Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KAKVFSYQVNHFBS-UHFFFAOYSA-N (5-hydroxycyclopenten-1-yl)-phenylmethanone Chemical compound OC1CCC=C1C(=O)C1=CC=CC=C1 KAKVFSYQVNHFBS-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LMMTVYUCEFJZLC-UHFFFAOYSA-N 1,3,5-pentanetriol Chemical compound OCCC(O)CCO LMMTVYUCEFJZLC-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LRZBIPQJHILPJI-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-(2,3-dihydroxypropyl)octadecanoate Chemical compound CCCCCCCCCCCCCCCCC(CC(O)CO)C(=O)OCC(O)CO LRZBIPQJHILPJI-UHFFFAOYSA-N 0.000 description 1
- WLMZUANPXHJWCH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dodecanoic acid Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCC(O)=O WLMZUANPXHJWCH-UHFFFAOYSA-N 0.000 description 1
- BIHQJMSIEXRWPS-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dodecyl dihydrogen phosphate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOP(O)(O)=O BIHQJMSIEXRWPS-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241001507009 Alpinia blepharocalyx Species 0.000 description 1
- 235000013411 Alpinia speciosa Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000041517 Etlingera elatior Species 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 240000004085 Kaempferia angustifolia Species 0.000 description 1
- 244000060701 Kaempferia pandurata Species 0.000 description 1
- 235000013412 Kaempferia pandurata Nutrition 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 1
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 241000639871 Piper dilatatum Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IHUMNXSBUOIDQI-UHFFFAOYSA-N Triethanolamine myristate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCCC(O)=O IHUMNXSBUOIDQI-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940054190 hydroxypropyl chitosan Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- PUGFCQQOYJMKOO-UHFFFAOYSA-N n-(3-hexadecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC PUGFCQQOYJMKOO-UHFFFAOYSA-N 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- RUOPINZRYMFPBF-UHFFFAOYSA-N pentane-1,3-diol Chemical compound CCC(O)CCO RUOPINZRYMFPBF-UHFFFAOYSA-N 0.000 description 1
- GLOBUAZSRIOKLN-UHFFFAOYSA-N pentane-1,4-diol Chemical compound CC(O)CCCO GLOBUAZSRIOKLN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- PYJBVGYZXWPIKK-UHFFFAOYSA-M potassium;tetradecanoate Chemical compound [K+].CCCCCCCCCCCCCC([O-])=O PYJBVGYZXWPIKK-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、カルダモニンを有効成分とするトランスグルタミナーゼ活性促進剤、インボルクリン生成促進剤、表皮角化正常化剤及び皮膚バリア機能改善剤に関するものである。 The present invention relates to a transglutaminase activity promoter, involucrin production promoter, epidermal keratinization normalizing agent, and skin barrier function improving agent containing cardamonin as an active ingredient.
表皮の角質層の最たる重要な機能として、体内の水分の蒸散や外界からの刺激や異物侵入を防ぐバリア機能が挙げられる。このバリア機能を発揮する角質層の構造は、角質細胞と細胞間脂質から構成される。より詳細には、角化細胞が分化誘導を受けることで、角化に必要なタンパク質（インボルクリンやロリクリン等）を合成され、次いでそれらタンパク質がトランスグルタミナーゼやＳＨオキシダーゼといった酵素により架橋されることで、角化細胞がタンパク質架橋体によって支持された細胞膜様構造体であるコーニファイドエンベロープが形成される。これにより安定な角質細胞の構造が構築される。そして構築された角質細胞の細胞間隙に細胞間脂質（セラミド、コレステロール、遊離脂肪酸等）が分泌及び配置され、生体内の水分蒸散を防ぐ役割を果たす。また角質層に含まれる水分中に天然保湿因子（ＮＭＦ）を発生させることで、角質層内の保湿性を維持させている。これらの過程を経ることで、実際のバリア機能を発揮する表皮の角質層が構築される。 The most important function of the stratum corneum of the epidermis is the barrier function that prevents transpiration of water in the body, irritation from the outside world, and entry of foreign substances. The structure of the stratum corneum that exhibits this barrier function is composed of corneocytes and intercellular lipids. More specifically, keratinocytes undergo differentiation induction to synthesize proteins necessary for keratinization (involucrin, loricrin, etc.), and then these proteins are cross-linked by enzymes such as transglutaminase and SH oxidase. A confined envelope is formed, which is a cell membrane-like structure in which keratinocytes are supported by protein bridges. Thereby, a stable keratinocyte structure is constructed. Then, intercellular lipids (ceramide, cholesterol, free fatty acids, etc.) are secreted and arranged in the interstices of the constructed keratinocytes, and play a role of preventing moisture evaporation in the living body. Moreover, the moisturizing property in the stratum corneum is maintained by generating a natural moisturizing factor (NMF) in the moisture contained in the stratum corneum. Through these processes, the stratum corneum of the epidermis that exhibits the actual barrier function is constructed.
ここで注意すべき点は、皮膚のバリア機能と保湿性は、角質層において明らかに関連するものではあるが、従来から使用されている保湿剤は、あくまで表皮に存在する水分の保持機能の上昇を目的とするものであり、角質層の細胞に対する作用ではなく、保湿剤それ自体の水分保持機能に依存するものである（非特許文献１）。それに対して、皮膚のバリア機能を修復、改善あるいは保持するためには、正常な角質層が構築されるように誘導する必要がある。そして、その角質層の構築において、外界の刺激である乾燥や紫外線、大気汚染物質や有機溶媒、アレルギー物質等に起因する化学的刺激や痛痒による引っ掻き等の物理的刺激が、角化細胞の正常な分化を阻害し、あるいは角質細胞の安定な構造に必要不可欠なタンパク質や酵素の合成や活性を阻害し、あるいは細胞間脂質の漏出や合成を阻害する。 It should be noted here that the skin barrier function and moisture retention are clearly related in the stratum corneum, but conventionally used moisturizers only increase the retention function of moisture present in the epidermis. It depends on the moisture retention function of the moisturizing agent itself, rather than acting on the cells of the stratum corneum (Non-patent Document 1). On the other hand, in order to repair, improve or maintain the barrier function of the skin, it is necessary to induce a normal stratum corneum to be constructed. In the construction of the stratum corneum, physical stimuli such as scratches caused by external stimuli such as dryness, ultraviolet rays, air pollutants, organic solvents, allergic substances, etc. Inhibits the differentiation, inhibits the synthesis and activity of proteins and enzymes essential for the stable structure of corneocytes, or inhibits leakage and synthesis of intercellular lipids.
よって、皮膚バリア機能を改善するためには、従来の保湿剤の作用とは異なる、角化細胞の正常な分化を誘導し、角質層の正常な構築の重要なファクターである細胞支持体となるインボルクリン等のタンパク質の生成を促進し、そのタンパク質の架橋化を司るトランスグルタミナーゼ等の活性化を促進するための方法が必要である。この方法の１つとして、これまでにサイシン抽出物やラフマ抽出物が有効であることが報告されているが（特許文献１）、皮膚バリア機能の改善に関する効果については、現状では更に優れたものが望まれている。 Therefore, in order to improve the skin barrier function, different from the action of the conventional moisturizing agent, it induces normal differentiation of keratinocytes and becomes a cell support that is an important factor for normal construction of the stratum corneum. There is a need for a method for promoting the production of proteins such as involucrin and for promoting the activation of transglutaminase and the like which is responsible for the cross-linking of the protein. As one of the methods, it has been reported that a saicin extract or a rafma extract is effective so far (Patent Document 1), but the effect on improving the skin barrier function is more excellent at present. Is desired.
従って、本発明の課題は、より優れたトランスグルタミナーゼ活性促進剤、インボルクリン生成促進剤、表皮角化正常化剤及び皮膚バリア機能改善剤の開発である。 Accordingly, an object of the present invention is to develop a more excellent transglutaminase activity promoter, involucrin production promoter, epidermal keratinization normalizing agent and skin barrier function improving agent.
本発明者らはカルダモニンに優れたトランスグルタミナーゼ活性促進作用及びインボルクリン生成促進作用があることを見いだした。またカルダモニンはアルピニア・カツマダイ抽出物の主要活性成分として既知であり、これらの知見より、本発明はカルダモニンを有効成分とする、あるいはカルダモニンをアルピニア・カツマダイ抽出物の形態で配合するトランスグルタミナーゼ活性促進剤、インボルクリン生成促進剤、表皮角化正常化剤及び皮膚バリア機能改善剤を提供するものである。 The present inventors have found that cardamonin has an excellent transglutaminase activity promoting action and involucrin production promoting action. Cardamomon is known as the main active ingredient of the extract of Alpinia katsudai, and based on these findings, the present invention is a transglutaminase activity promoter containing cardamonin as an active ingredient or containing cardamonin in the form of an alpinia katsudai extract. , An involucrin production promoter, an epidermal keratinizing normalizing agent, and a skin barrier function improving agent.
本発明は優れたトランスグルタミナーゼ活性促進作用及びインボルクリン生成促進作用を有する。そしてこれらの作用が発揮される結果として、表皮の角化が正常化し、皮膚のバリア機能が著しく改善されるものである。 The present invention has an excellent transglutaminase activity promoting action and involucrin production promoting action. As a result of exerting these actions, the keratinization of the epidermis is normalized, and the barrier function of the skin is remarkably improved.
本発明で用いられるカルダモニンは以下に示す構造を有する。
本発明のカルダモニンは、一般的な化学合成法を適宜組み合わせて製造して得られるが、その工程数の多さと複雑さから、一般にはアルピニア属植物、例えばアルピニア・カツマダイ（Alpinia katsumadai H．生薬名：ソウズク）やゲットウ（Alpinia speciosa K．Schum）、アルピニア・ベルファロカリクス（Alpinia blepharocalyx）、ヒダカミツバツツジ(Piper dilatatum)、オオバンガジュツ(Boesenbergia pandurata)、ヴィテックス・レプトボトリス（Vitex leptobotrys）、ケンフェリア・アンガスティフォリア（Kaempferia angustifolia）、その他同属植物などから抽出精製して製造される。上記植物の中で、特にアルピニア・カツマダイにおいてカルダモニンの含有量が高く、本発明で使用するカルダモニンは、アルピニア・カツマダイの抽出物の形態で同等に用いることができる。 The cardamonin of the present invention can be obtained by appropriately combining general chemical synthesis methods, but due to the large number of steps and complexity, generally, the plant of the genus Alpinia, such as Alpinia katsumadai H. : Alpinia speciosa K. Schum, Alpinia blepharocalyx, Piper dilatatum, Boesenbergia pandurata, Vitex leptobotry, Vitex leptobots, Vitex leptobotry Manufactured by extraction and purification from tifolia (Kaempferia angustifolia) and other related plants. Among the above plants, the content of cardamonin is particularly high in alpinia katsudai, and the cardamonin used in the present invention can be used in the form of an extract of alpinia katsudai.
前記のアルピニア・カツマダイの抽出物は、ショウガ科アルピニア・カツマダイ（Alpinia katsumadai Hayata）の花、花柱、雄花、雌花、花穂、頭花、穎果、果皮、果実、茎、葉、枝、枝葉、幹、樹皮、根、根茎、根皮等から選択される少なくとも１以上の部位を、そのままあるいは粉砕後、溶媒で抽出したものであるが、特にカルダモニンの含有量が非常に高い部位である種子を用いることが好ましい。抽出物の形状としては、液状、固形状、粉末状、ペースト状等いずれの形状でも良く、本発明を実施する上で最適な形状を適宜に選択する。 The above-mentioned extract of Alpinia katsumadai is a flower, style, male flower, female flower, spikelet, head flower, pericarp, pericarp, fruit, stem, leaf, branch, branch leaf, stem of the ginger family Alpinia katsumadai Hayata. At least one part selected from bark, root, rhizome, root bark, etc. is extracted with a solvent as it is or after pulverization, but in particular, a seed having a very high cardamonin content is used. It is preferable. The shape of the extract may be any shape such as liquid, solid, powder, paste, and the like, and an optimum shape is appropriately selected for carrying out the present invention.
前記抽出物を得るための抽出溶媒としては、水、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール、ブタノール、イソブタノール等の低級アルコール或いは含水低級アルコール、プロピレングリコール、1,3-ブチレングリコール、1,2-ブチレングリコール、1,4-ブチレングリコール、1,5-ペンタンジオール、1,2-ペンタンジオール、1,3-ペンタンジオール、1,4-ペンタンジオール、1,3,5-ペンタントリオール、グリセリン、ポリエチレングリコール（分子量100〜10万）等の多価アルコールあるいは含水多価アルコール、アセトン、酢酸エチル、ジエチルエーテル、ジメチルエーテル、エチルメチルエーテル、ジオキサン、アセトニトリル、キシレン、ベンゼン、クロロホルム、四塩化炭素、フェノール、トルエン等の各種有機溶媒や、適宜規定度を調製した酸（塩酸、硫酸、硝酸、リン酸、ギ酸、酢酸等）やアルカリ（水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、アンモニア等）の中から選ばれる１種もしくは２種以上の混液が挙げられ、特に水、エタノール及び1,3-ブチレングリコールから選ばれる１種又は２種以上を選択することが好ましい。但し、用途により溶媒の含有が好ましくない場合においては、水のみを使用するか、あるいは抽出後に溶媒を除去しやすい、揮発性の高い溶媒を用いて抽出を行い、溶媒除去後水等に溶解させるといった方法も可能である。 Examples of the extraction solvent for obtaining the extract include water, lower alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol and isobutanol, or water-containing lower alcohols, propylene glycol, 1,3-butylene glycol, 1,2 -Butylene glycol, 1,4-butylene glycol, 1,5-pentanediol, 1,2-pentanediol, 1,3-pentanediol, 1,4-pentanediol, 1,3,5-pentanetriol, glycerin, Polyhydric alcohol such as polyethylene glycol (molecular weight: 100 to 100,000) or hydrous polyhydric alcohol, acetone, ethyl acetate, diethyl ether, dimethyl ether, ethyl methyl ether, dioxane, acetonitrile, xylene, benzene, chloroform, carbon tetrachloride, phenol, Various organic solvents such as toluene 1 type or 2 selected from acids (hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, etc.) and alkalis (sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonia, etc.) with appropriate normality A mixture of two or more species can be mentioned, and it is particularly preferable to select one or more types selected from water, ethanol and 1,3-butylene glycol. However, if it is not preferable to use a solvent depending on the application, use water alone or extract with a highly volatile solvent that is easy to remove the solvent after extraction and dissolve in water after removing the solvent. Such a method is also possible.
抽出方法については、その溶媒の温度や原料に対する溶媒の重量比率、又は抽出時間についても、種々の原料及び使用する溶媒に対しそれぞれを任意に設定することができる。溶媒の温度としては−４℃から１００℃の範囲で任意に設定できるが、原料中に含まれるカルダモニンの安定性の点から、１０〜４０℃付近が好ましい。又、原料に対する溶媒の重量比率も、例えば原料：溶媒が、４：１〜１：１００の範囲内で任意に設定することができ、特に１：１〜１：２０の重量比率が好ましい。 Regarding the extraction method, the temperature of the solvent, the weight ratio of the solvent to the raw material, or the extraction time can be arbitrarily set for various raw materials and the solvent used. The temperature of the solvent can be arbitrarily set in the range of −4 ° C. to 100 ° C., but is preferably about 10 to 40 ° C. from the viewpoint of the stability of cardamonin contained in the raw material. Also, the weight ratio of the solvent to the raw material can be arbitrarily set, for example, in the range of the raw material: solvent 4: 1 to 1: 100, and the weight ratio of 1: 1 to 1:20 is particularly preferable.
本発明で用いる前記抽出物は、溶媒抽出後、更に適宜精製操作を施したものも、定義の範囲に包含する。精製操作としては、酸（塩酸、硫酸、硝酸、リン酸、有機酸等）又はアルカリ（水酸化ナトリウム、水酸化カルシウム、アンモニア等）添加による分解、微生物による発酵又は代謝変換、イオン交換樹脂や活性炭、ケイ藻土等による成分吸着、種々の分離モード（イオン交換、親水性吸着、疎水性吸着、サイズ排除、配位子交換、アフィニティー等）を有するクロマトグラフィーを用いた分画、濾紙やメンブランフィルター、限外濾過膜等を用いた濾過、加圧又は減圧、加温又は冷却、乾燥、ｐＨ調整、脱臭、脱色、長時間の静置保管等が例示でき、これらを任意に選択し組合わせた処理を行うことが可能である。 The extract used in the present invention includes those subjected to solvent purification and further subjected to appropriate purification operations within the scope of the definition. Purification operations include decomposition by adding acid (hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, organic acid, etc.) or alkali (sodium hydroxide, calcium hydroxide, ammonia, etc.), fermentation or metabolic conversion by microorganisms, ion exchange resin or activated carbon. , Component adsorption by diatomaceous earth, etc., fractionation using chromatography with various separation modes (ion exchange, hydrophilic adsorption, hydrophobic adsorption, size exclusion, ligand exchange, affinity, etc.), filter paper and membrane filter Examples include filtration using an ultrafiltration membrane, pressurization or depressurization, heating or cooling, drying, pH adjustment, deodorization, decolorization, long-time storage, etc., which are arbitrarily selected and combined Processing can be performed.
本発明のトランスグルタミナーゼ活性促進剤、インボルクリン生成促進剤、表皮角化正常化剤及び皮膚バリア機能改善剤への、カルダモニンあるいはアルピニア・カツマダイ抽出物の含有量は特に限定されないが、0.0001〜20質量％の範囲であることが好ましく、特に0.001〜2質量％の範囲であることが好ましい。0.0001質量％未満では発現する効果が著しく低く、また20質量％を超えても効果に大きな増強はみられない。これらの各剤は、非経口的、特に経皮的に投与可能なものであれば特に制限はなく、カプセル状、粉末状、顆粒状、固形状、液状、ゲル状、気泡状、乳液状、クリーム状、軟膏状、シート状、ムース状、粉末分散状、多層状、エアゾール状等から任意の剤型を成す。 The content of cardamonin or alpinia katsudai extract in the transglutaminase activity promoter, involucrin production promoter, epidermal keratinization normalizer and skin barrier function improver of the present invention is not particularly limited, but is 0.0001 to 20% by mass. It is preferable that it is the range of 0.001-2 mass% especially. If the amount is less than 0.0001% by mass, the effect is remarkably low, and if it exceeds 20% by mass, the effect is not greatly enhanced. Each of these agents is not particularly limited as long as it can be administered parenterally, particularly transdermally. Capsule, powder, granule, solid, liquid, gel, foam, emulsion, Any dosage form may be formed from cream, ointment, sheet, mousse, powder dispersion, multilayer, aerosol, and the like.
本発明の各剤は、それ自体が外用製剤となり得る他、化粧品類や医薬部外品類の製造における添加成分としても使用される。外用の形態としては、具体的には化粧水、乳液、クリーム、ローション、パック、石鹸やボディーシャンプー、洗顔料、口紅、ファンデーション、シャンプー、リンス、トリートメント、ヘアローション、ヘアリキッド、ヘアトニック等の化粧品類が挙げられる。また軟膏や貼付剤、ローション剤、パップ剤、リニメント剤等の医薬品類並びに医薬部外品類が挙げられる。化粧品類や医薬部外品類における本発明の含有量は、0.001〜50質量％の範囲である。 Each agent of the present invention itself can be used as an external preparation, and is also used as an additive component in the production of cosmetics and quasi drugs. Examples of external forms include cosmetics such as lotions, emulsions, creams, lotions, packs, soaps and body shampoos, face wash, lipsticks, foundations, shampoos, rinses, treatments, hair lotions, hair liquids, hair tonics, etc. Kind. Further, pharmaceuticals such as ointments, patches, lotions, poultices, liniments, and quasi-drugs may be mentioned. The content of the present invention in cosmetics and quasi drugs is in the range of 0.001 to 50% by mass.
前記の化粧品類や医薬部外品類を製造する上で、必須な有効成分である本発明で用いるカルダモニン又はアルピニア・カツマダイ抽出物以外に、それらの効果を損なわない範囲内で、通常の化粧品や医薬部外品に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、ｐＨ調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤等の成分を配合することもできる。製剤中における各種成分の含有量は、特に限定されないが、通常、0.0001〜50重量％の濃度範囲が一般的である。 Other than cardamomonin or alpinia katsudai extract used in the present invention, which is an essential active ingredient in producing the above-mentioned cosmetics and quasi-drugs, ordinary cosmetics and pharmaceuticals are used as long as their effects are not impaired. Fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, metal soaps, pH adjusters, antiseptics, perfumes, moisturizers, powders, which are components used in quasi-drugs Components such as an ultraviolet absorber, a thickener, a dye, an antioxidant, a whitening agent, and a chelating agent can be blended. The content of various components in the preparation is not particularly limited, but usually a concentration range of 0.0001 to 50% by weight is common.
以下に実施例を挙げて本発明を更に詳細に説明するが、本発明はこれらになんら制約されるものではない。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
［製造例１］
アルピニア・カツマダイ抽出物の製造
アルピニア・カツマダイの種子（ソウズク）100gに1.0Lの50％エタノール水溶液を加え、常温下にて７日間浸漬抽出した。次いで濾紙を用いて濾過し、不溶物を除去することでアルピニア・カツマダイ抽出物1.0kgを得た。
[Production Example 1]
Manufacture of extract of Alpinia kumamadai 1.0 L of 50% ethanol aqueous solution was added to 100 g of seeds of Alpinia katsumadai (sawberry) and extracted by immersion for 7 days at room temperature. Subsequently, it filtered using the filter paper and 1.0 kg of Alpinia katsudai extract was obtained by removing an insoluble matter.
［製造例２］
カルダモニンの製造
製造例１で得られたアルピニア・カツマダイ抽出物500mLを合成吸着樹脂（ダイアイオンHP20）に吸着させた後、エタノール水溶液で洗浄後、エタノールで溶出した。エタノール溶出分画をシリカゲルカラムクロマトグラフィーに付し、クロロホルム−メタノール溶媒で、混合比率を変えながら溶出を行った。更にこのうち活性の最も強い分画をHPLCにより紫外線280並びに330nmの吸収波長を指標に、各ピーク毎に分画を行った。これらの分画について活性を評価し、もっとも強い分画を選ぶことで、カルダモニンの黄色結晶3mgを得た。
MSスペクトル（JMS-DX300（JEOL）），EIMS m/z (rel.int.)：270（48，M+）
NMRスペクトル（JNM-AL-400（JEOL））
1H-NMR（400MHz，acetone-d6）：3.92（3H，s，C6’-OCH3），5.87 （1H，d，J=2Hz，C3'-H），5.95（1H，d，J=2Hz，C5'-H），7.39-7.45，7.66-7.70，（5H，m，C2-C6-H），7.68，8.05 (1H, d, J=16Hz, CH=CH)，14.10（1H，brs，C2'-OH）
[Production Example 2]
Production of cardamonin After 500 mL of the Alpinia katsudai extract obtained in Production Example 1 was adsorbed on a synthetic adsorption resin (Diaion HP20), it was washed with an aqueous ethanol solution and then eluted with ethanol. The ethanol elution fraction was subjected to silica gel column chromatography and eluted with a chloroform-methanol solvent while changing the mixing ratio. Further, among the fractions having the highest activity, fractionation was performed for each peak by HPLC using UV 280 and an absorption wavelength of 330 nm as indices. By evaluating the activity of these fractions and selecting the strongest fraction, 3 mg of cardamonin yellow crystals were obtained.
MS spectrum (JMS-DX300 (JEOL)), EIMS m / z (rel.int.): 270 (48, M + )
NMR spectrum (JNM-AL-400 (JEOL))
1 H-NMR (400 MHz, acetone-d 6 ): 3.92 (3H, s, C6′-OCH 3 ), 5.87 (1H, d, J = 2 Hz, C3′-H), 5.95 (1H, d, J = 2Hz, C5'-H), 7.39-7.45, 7.66-7.70, (5H, m, C2-C6-H), 7.68, 8.05 (1H, d, J = 16Hz, CH = CH), 14.10 (1H, brs , C2'-OH)
［実施例１］
表皮細胞用培地（Epilife，クラボウ社製）を用いて、ヒト表皮角化細胞（クラボウ社製）を60mmディッシュに播種し、サブコンフルエントまで培養した後、製造例１のアルピニア・カツマダイ抽出物50μg/mL、又は製造例２のカルダモニン1μg/mLを添加した。陰性対照は製造例１に対しては50％エタノール、製造例２に対してはエタノールを用いた。製造例１又は製造例２又は陰性対照を培地に添加後、24時間培養した後細胞を回収し、RIPA（10mM Tris-HCl，pH7.5，1.0％Nonidet P-40，0.1％Sodium deoxycholate，0.1％SDS，150mM NaCl，1mM EDTA）に溶解し、細胞抽出液を調整した。次に、細胞溶解物をSDS-ポリアクリルアミドゲルで分離し、その後、角化マーカーであるインボルクリン抗体及びトランスグルタミナーゼ抗体を用いてウエスタンブロッティングを行った。そして得られたバンドの強度をデンシトメトリー解析し、陰性対照との強度比を算出した。
[Example 1]
Using epidermal cell culture medium (Epilife, Kurabo Industries), human epidermal keratinocytes (Kurabo) are seeded in 60 mm dishes and cultured to subconfluence, and then Alpinia katsudai extract of Production Example 1 50 μg / mL or 1 μg / mL of cardamonin of Production Example 2 was added. Negative control was 50% ethanol for Production Example 1 and ethanol for Production Example 2. After adding Production Example 1 or Production Example 2 or a negative control to the medium and culturing for 24 hours, the cells were collected, and RIPA (10 mM Tris-HCl, pH 7.5, 1.0% Nonidet P-40, 0.1% Sodium deoxycholate, 0.1 % SDS, 150 mM NaCl, 1 mM EDTA) to prepare a cell extract. Next, the cell lysate was separated by SDS-polyacrylamide gel, and then Western blotting was performed using an involucrin antibody and a transglutaminase antibody as keratinized markers. The intensity of the obtained band was analyzed by densitometry, and the intensity ratio with the negative control was calculated.
［実施例１の結果］
カルダモニンをヒト表皮角化細胞に添加した結果、陰性対照と比較してインボルクリンの発現が1.4倍、トランスグルタミナーゼの発現が1.6倍上昇した。またアルピニア・カツマダイ抽出物を添加した結果、陰性対照と比較してインボルクリンの発現が3.6倍、トランスグルタミナーゼの発現が1.9倍上昇した。以上の結果より、本発明で用いるカルダモニン及びアルピニア・カツマダイ抽出物は、優れたトランスグルタミナーゼ活性促進作用及びインボルクリン生成促進作用を有するものであった。
[Results of Example 1]
As a result of adding cardamomon to human epidermal keratinocytes, involucrin expression was increased 1.4-fold and transglutaminase expression was increased 1.6-fold compared to the negative control. In addition, as a result of adding Alpinia katsudai extract, involucrin expression was increased 3.6 times and transglutaminase expression was increased 1.9 times compared to the negative control. From the above results, cardamonin and alpinia katsudai extract used in the present invention have excellent transglutaminase activity promoting action and involculin production promoting action.
（各種製剤の製造例）
本発明である様々な剤形の製剤を製造した。以下にその処方例を示すが、本発明はこれらに限定されるわけではない。
(Manufacturing examples of various preparations)
Various dosage forms of the present invention were prepared. Although the formulation example is shown below, this invention is not necessarily limited to these.
（処方例１）乳液 重量％
ポリエーテル変性オルガノポリシロキサン 5.0
モノステアリン酸ジグリセリル 1.5
デカメチルシクロテトラシロキサン 20.0
ジメチルポリシロキサン 10.0
流動パラフィン 10.0
香料 0.1
製造例２のカルダモニン 0.05
1,3-ブチレングリコール 15.0
塩化ナトリウム 0.2
精製水 残量 (Formulation Example 1) Emulsion weight%
Polyether-modified organopolysiloxane 5.0
Diglyceryl monostearate 1.5
Decamethylcyclotetrasiloxane 20.0
Dimethylpolysiloxane 10.0
Liquid paraffin 10.0
Fragrance 0.1
Cardamonin of Production Example 2 0.05
1,3-butylene glycol 15.0
Sodium chloride 0.2
Purified water remaining
（処方例２）クリーム 重量％
ワセリン 8.0
N-(3-ヘキサデシロキシ-2-ヒドロキシプロピル)
-N-2-ヒドロキシエチルヘキサデカナミド 2.0
スクワレン 20.0
セタノール 5.0
モノステアリン酸グリセリン 2.0
ポリオキシエチレン(20)
モノラウリン酸ソルビタン 2.0
アルギニン 0.1
セラミド３ 0.5
リン酸一水素ナトリウム 0.85
製造例２のカルダモニン 0.05
グリセリン 5.0
1,3-ブチレングリコール 5.0
ジメチルポリシロキサン 3.0
香料 0.1
精製水 残量 (Formulation example 2) Cream weight%
Vaseline 8.0
N- (3-hexadecyloxy-2-hydroxypropyl)
-N-2-Hydroxyethylhexadecanamide 2.0
Squalene 20.0
Cetanol 5.0
Glycerol monostearate2.0
Polyoxyethylene (20)
Sorbitan monolaurate 2.0
Arginine 0.1
Ceramide 3 0.5
Sodium monohydrogen phosphate 0.85
Cardamonin of Production Example 2 0.05
Glycerin 5.0
1,3-butylene glycol 5.0
Dimethylpolysiloxane 3.0
Fragrance 0.1
Purified water remaining
（処方例３）化粧水 重量％
ソルビトール 2.0
1,3-ブチレングリコール 4.0
アルピニア・カツマダイ抽出物 0.08
ポリオキシエチレン(25)オレイルエーテル 2.0
カルボキシビニルポリマー 0.2
エタノール 15.0
精製水 残量 (Formulation example 3) Lotion weight%
Sorbitol 2.0
1,3-butylene glycol 4.0
Alpinia bonito extract 0.08
Polyoxyethylene (25) oleyl ether 2.0
Carboxyvinyl polymer 0.2
Ethanol 15.0
Purified water remaining
（処方例４）ファンデーション 重量％
デカメチルシクロペンタシロキサン 45.0
ジメチルポリシロキサン 5.0
ジメチルジステアリル
アンモニウムヘクトライト 4.0
疎水化処理酸化チタン 10.0
疎水化処理タルク 6.0
疎水化処理マイカ 6.0
疎水化処理ベンガラ 1.6
疎水化処理黄酸化鉄 0.7
疎水化処理黒酸化鉄 0.2
アルピニア・カツマダイ抽出物 3.0
ジプロピレングリコール 5.0
2-アミノ-2-メチル-1,3-プロパンジオール 0.5
香料 0.1
精製水 残量 (Formulation Example 4) Foundation weight%
Decamethylcyclopentasiloxane 45.0
Dimethylpolysiloxane 5.0
Dimethyl distearyl ammonium hectorite 4.0
Hydrophobized titanium oxide 10.0
Hydrophobic talc 6.0
Hydrophobized mica 6.0
Hydrophobic treatment Bengala 1.6
Hydrophobized yellow iron oxide 0.7
Hydrophobized black iron oxide 0.2
Alpinia bonito extract 3.0
Dipropylene glycol 5.0
2-Amino-2-methyl-1,3-propanediol 0.5
Fragrance 0.1
Purified water remaining
（処方例５）洗顔料 重量％
ラウリルホスフェートトリエタノールアミン 18.0
ラウリン酸トリエタノールアミン 2.5
ミリスチン酸トリエタノールアミン 2.5
アルピニア・カツマダイ抽出物 4.0
グリセリン 16.0
トリイソステアリン酸
ポリオキシエチレン(160)ソルビタン 2.0
カチオン化セルロース 0.5
アクリル酸メタクリル酸アルキル共重合体 0.5
ラウリルヒドロキシスルホベタイン 5.0
香料 0.1
精製水 残量 (Formulation Example 5) Face wash weight%
Lauryl phosphate triethanolamine 18.0
Lauric acid triethanolamine 2.5
Myristic acid triethanolamine 2.5
Alpinia bonito extract 4.0
Glycerin 16.0
Triisostearic acid polyoxyethylene (160) sorbitan 2.0
Cationized cellulose 0.5
Acrylic acid methacrylate alkyl copolymer 0.5
Lauryl hydroxysulfobetaine 5.0
Fragrance 0.1
Purified water remaining
（処方例６）シャンプー 重量％
クエン酸ナトリウム 2.0
N-アセチルグルタミン酸 1.0
ラウリン酸カリウム 15.0
ミリスチン酸カリウム 5.0
カルダモニン 0.4
プロピレングリコール 5.0
ソルビトール 3.0
メチルポリシロキサン 1.5
アミノ変性ジメチルポリシロキサン 2.5
ポリエチレン末 0.5
ヒドロキシプロピルキトサン 0.5
香料 0.1
精製水 残量 (Formulation Example 6) Shampoo Weight%
Sodium citrate 2.0
N-acetylglutamic acid 1.0
Potassium laurate 15.0
Potassium myristate 5.0
Cardamonin 0.4
Propylene glycol 5.0
Sorbitol 3.0
Methylpolysiloxane 1.5
Amino-modified dimethylpolysiloxane 2.5
Polyethylene powder 0.5
Hydroxypropyl chitosan 0.5
Fragrance 0.1
Purified water remaining
（処方例７）軟膏 重量％
l-メントール 3.0
DL-カンフル 0.5
カルダモニン 5.0
プロピレングリコール 15.0
カルボキシビニルポリマー 1.0
ヒドロキシエチルセルロース 0.1
トリエタノールアミン 0.7
精製水 25.0
エタノール 100とする残量 (Prescription Example 7) Ointment Weight%
l-Menthol 3.0
DL-Camphor 0.5
Cardamonin 5.0
Propylene glycol 15.0
Carboxyvinyl polymer 1.0
Hydroxyethyl cellulose 0.1
Triethanolamine 0.7
Purified water 25.0
Remaining amount of ethanol 100
（処方例８）貼付剤 重量％
l-メントール 3.0
DL-カンフル 1.5
ポリアクリル酸 4.5
ポリアクリル酸ナトリウム 1.5
カルボキシメチルセルロースナトリウム 4.0
カルダモニン 1.5
グリセリン 20.0
ソルビトール 5.0
ポリオキシエチレンノニルフェニルエーテル 0.5
カオリン 5.0
ヒマシ油 1.0
精製水 残量
上記成分を溶解、分散及び練合したものを、ポリエステル不織布に1m2当たり、1000gとなるよう展延し、貼付剤を製造した。
(Prescription Example 8) Patch%
l-Menthol 3.0
DL-Camphor 1.5
Polyacrylic acid 4.5
Sodium polyacrylate 1.5
Sodium carboxymethylcellulose 4.0
Cardamonin 1.5
Glycerin 20.0
Sorbitol 5.0
Polyoxyethylene nonylphenyl ether 0.5
Kaolin 5.0
Castor oil 1.0
Purified water remaining The above-mentioned components dissolved, dispersed and kneaded were spread on a polyester non-woven fabric so as to be 1000 g per 1 m 2 to produce a patch.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008188199A JP2010024190A (en) | 2008-07-22 | 2008-07-22 | Skin barrier function ameliorator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008188199A JP2010024190A (en) | 2008-07-22 | 2008-07-22 | Skin barrier function ameliorator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2010024190A true JP2010024190A (en) | 2010-02-04 |
Family
ID=41730334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008188199A Pending JP2010024190A (en) | 2008-07-22 | 2008-07-22 | Skin barrier function ameliorator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2010024190A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014062090A (en) * | 2012-08-29 | 2014-04-10 | Kao Corp | Transglutaminase activator |
| JP2014062089A (en) * | 2012-08-29 | 2014-04-10 | Kao Corp | Transglutaminase activator |
| US10064800B2 (en) | 2012-08-29 | 2018-09-04 | Kao Corporation | Transglutaminase activator |
-
2008
- 2008-07-22 JP JP2008188199A patent/JP2010024190A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014062090A (en) * | 2012-08-29 | 2014-04-10 | Kao Corp | Transglutaminase activator |
| JP2014062089A (en) * | 2012-08-29 | 2014-04-10 | Kao Corp | Transglutaminase activator |
| US10064800B2 (en) | 2012-08-29 | 2018-09-04 | Kao Corporation | Transglutaminase activator |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090042846A1 (en) | Topical Delivery System for Phytosterols | |
| JP2005504755A (en) | Cosmetic and / or pharmaceutical preparations containing plant extracts | |
| KR101885195B1 (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| CN102665709A (en) | Skin clarifying complex, use of said complex, cosmestic or pharmaceutical composition comprising said complex and method for application thereof | |
| JPH10330280A (en) | Promoter for producing collagen, and skin preparation for external use for preventing aging containing the same | |
| JP2010024190A (en) | Skin barrier function ameliorator | |
| JP2015093848A (en) | Skin cosmetic and hair cosmetic | |
| JP2005008548A (en) | Skin preparation | |
| JP2008094792A (en) | Hyaluronic acid synthesis promoter, anti-aging agent and skin care preparation each containing commelina communis var. hortensis-derived flavonoid | |
| KR101418979B1 (en) | Composition for accelerating collagen formation and cosmetics using the same | |
| KR101776692B1 (en) | Composiitn for skin whitening comprising extract of Osmanthus heterophylla | |
| JP5946698B2 (en) | Whitening agent and skin cosmetics | |
| JP2006257058A (en) | Lipase inhibitor, and hair preparation and skin external preparation containing the same. | |
| JP2002284648A (en) | Hair restorer composition | |
| JP2004307437A (en) | Skin care preparation for external use for preventing aging | |
| JP3822959B2 (en) | Anti-aging skin external preparation | |
| KR101427027B1 (en) | A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis | |
| JP2019108278A (en) | Wrinkle improver | |
| CN108348449B (en) | Anti-aging skin external composition containing extract of germinated semi-wild soybean as effective component | |
| JP2009114146A (en) | Transglutaminase-1 production promoter and involucrin production promoter | |
| JP2006083112A (en) | Skin care preparation for external use | |
| JP3754025B2 (en) | Cell activator, antioxidant, and skin external preparation | |
| KR102371164B1 (en) | Skin external composition for anti-aging containing germinated Glycine gracilis extract | |
| JP4886878B2 (en) | Tyrosinase activity inhibitor and whitening cosmetic | |
| JP7451005B1 (en) | Preadipocyte proliferation and/or differentiation promoter containing a helenalin derivative |